Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
12.46
-5.48 (-30.54%)
At close: Apr 28, 2026, 4:00 PM EDT
13.57
+1.12 (8.95%)
After-hours: Apr 28, 2026, 7:58 PM EDT
Cue Biopharma Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Cue Biopharma stock has a target of 120, which predicts an increase of 863.47% from the current stock price of 12.46.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 25, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Cue Biopharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LUCID CAPITAL MARKETS | LUCID CAPITAL MARKETS | Strong Buy Initiates $120 | Strong Buy | Initiates | $120 | +863.47% | Aug 25, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $60 | Buy | Reiterates | $60 | +381.73% | Apr 2, 2025 |
| Stifel | Stifel | Strong Buy Maintains $240 → $120 | Strong Buy | Maintains | $240 → $120 | +863.47% | Aug 20, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $450 → $60 | Buy | Maintains | $450 → $60 | +381.73% | Jul 26, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $240 → $90 | Buy | Maintains | $240 → $90 | +622.60% | Jul 26, 2024 |
Financial Forecast
Revenue This Year
1.01M
from 27.47M
Decreased by -96.32%
Revenue Next Year
1.01M
from 1.01M
EPS This Year
-0.59
from -8.42
EPS Next Year
-0.61
from -0.59
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.1M | 1.1M | ||||||
| Avg | 1.0M | 1.0M | ||||||
| Low | 980,000 | 980,000 |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -96.2% | 4.0% | ||||||
| Avg | -96.3% | - | ||||||
| Low | -96.4% | -3.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.61 | -0.63 | |
| Avg | -0.59 | -0.61 | |
| Low | -0.57 | -0.59 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.